USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: OSTEOGENEX, INC
City: Kansas city
State: KS
Zip+4: 66103-
Woman-Owned: Yes
Minority-Owned: No
HUBZone-Owned: No
Website URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $608,980.00 2
SBIR Phase II $994,943.00 1

Award List:

Therapeutics for increasing Bone Density and Quality

Award Year / Program / Phase: 2006 / SBIR / Phase I
Agency: HHS
Principal Investigator: Debra L. Ellies
Award Amount: $133,904.00
Abstract:
DESCRIPTION (provided by applicant): Osteoporosis affects 55% of Americans over the age of 50, and incurs a medical cost of $47 million a day. It is caused by a disruption in the fine equilibrium between bone resorption and bone deposition. Currently, the most successful pharmaceutical drugs for… More

Anabolic Therapeutics for Increasing Bone Denisty and Quality

Award Year / Program / Phase: 2008 / SBIR / Phase II
Agency: HHS
Principal Investigator:
Award Amount: $994,943.00
Abstract:
DESCRIPTION (provided by applicant): OsteoGeneX is developing a therapeutic directed against the new bone target Sclerostin (SOST) for the treatment of osteoporosis and related bone disorders. Through genomic approaches Sclerostin was identified as a mast er regulator of bone mass affecting men and… More

Oral delivered bone building therapy for osteoporosis

Award Year / Program / Phase: 2013 / SBIR / Phase I
Agency: HHS
Principal Investigator: Debra L. Ellies – 913-945-6763
Award Amount: $475,076.00
Abstract:
DESCRIPTION (provided by applicant): The osteoporosis market is still in demand for new therapeutics due to the lack of safe orally available bone building drugs. Currently, parathyroid hormone (PTH; FORTEOTM) and its analogs are the only bone building therapies available yet they capture only 8% of… More